Cellebrite DI (CLBT) Capital Expenditures (2020 - 2025)

Cellebrite DI's Capital Expenditures history runs 6 years deep, the most recent figure standing at -$4.0 million for Q4 2025.

• On a quarterly basis, Capital Expenditures fell 24.48% year-over-year to -$4.0 million in Q4 2025; TTM through Dec 2025 was -$13.2 million, a 54.39% decrease from a year earlier, with the FY2025 full-year figure at $13.2 million, up 3778.3% from the prior year.
• Capital Expenditures fell to -$4.0 million in Q4 2025 per CLBT's latest filing, from -$3.3 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $749000.0 in Q4 2021 and bottomed at -$4.0 million in Q4 2025.
• The 5-year median for Capital Expenditures is -$1.2 million (2022), against an average of -$1.4 million.
• Across the five-year window, Capital Expenditures soared 1024.69% in 2021 and slumped 1469.62% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at $749000.0 in 2021, then plunged by 285.71% to -$1.4 million in 2022, then sank by 62.47% to -$2.3 million in 2023, then slumped by 40.62% to -$3.2 million in 2024, then dropped by 24.48% to -$4.0 million in 2025.
• Per Business Quant, the three latest CLBT Capital Expenditures figures stand at -$4.0 million (Q4 2025), -$3.3 million (Q3 2025), and -$3.6 million (Q2 2025).